ERAS
Price
$1.74
Change
+$0.03 (+1.75%)
Updated
Jul 25 closing price
Capitalization
492.92M
10 days until earnings call
SVRA
Price
$2.58
Change
+$0.03 (+1.18%)
Updated
Jul 25 closing price
Capitalization
445.92M
10 days until earnings call
Interact to see
Advertisement

ERAS vs SVRA

Header iconERAS vs SVRA Comparison
Open Charts ERAS vs SVRABanner chart's image
Erasca
Price$1.74
Change+$0.03 (+1.75%)
Volume$654.4K
Capitalization492.92M
Savara
Price$2.58
Change+$0.03 (+1.18%)
Volume$735.75K
Capitalization445.92M
ERAS vs SVRA Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. SVRA commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and SVRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ERAS: $1.74 vs. SVRA: $2.58)
Brand notoriety: ERAS and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 54% vs. SVRA: 41%
Market capitalization -- ERAS: $492.92M vs. SVRA: $445.92M
ERAS [@Biotechnology] is valued at $492.92M. SVRA’s [@Biotechnology] market capitalization is $445.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than SVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while SVRA’s TA Score has 6 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 4 bearish.
  • SVRA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SVRA is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +16.00% price change this week, while SVRA (@Biotechnology) price change was +14.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.47%. For the same industry, the average monthly price growth was +22.83%, and the average quarterly price growth was +43.96%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

SVRA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($493M) has a higher market cap than SVRA($446M). SVRA YTD gains are higher at: -15.961 vs. ERAS (-30.677). SVRA has higher annual earnings (EBITDA): -108.24M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. SVRA (172M). SVRA has less debt than ERAS: SVRA (29.6M) vs ERAS (50.8M). ERAS (0) and SVRA (0) have equivalent revenues.
ERASSVRAERAS / SVRA
Capitalization493M446M111%
EBITDA-150.24M-108.24M139%
Gain YTD-30.677-15.961192%
P/E RatioN/AN/A-
Revenue00-
Total Cash305M172M177%
Total Debt50.8M29.6M172%
FUNDAMENTALS RATINGS
SVRA: Fundamental Ratings
SVRA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASSVRA
RSI
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 7 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
73%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 18 days ago
88%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
87%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTEAF0.790.02
+2.09%
DAVIDsTEA Inc
ANOHX25.230.15
+0.60%
American Century Small Cap Growth G
CGAEX12.730.07
+0.55%
Calvert Global Energy Solutions A
EVSIX25.930.13
+0.50%
Allspring Disciplined US Core Inst
MNHRX26.790.09
+0.34%
Manning & Napier Pro-Blend Max Term R

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.75%
XNCR - ERAS
54%
Loosely correlated
N/A
RVMD - ERAS
54%
Loosely correlated
N/A
OCUL - ERAS
53%
Loosely correlated
+2.43%
BEAM - ERAS
53%
Loosely correlated
+3.68%
LRMR - ERAS
50%
Loosely correlated
+3.47%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
+1.18%
RCKT - SVRA
62%
Loosely correlated
-2.18%
PRTA - SVRA
46%
Loosely correlated
-0.30%
RVMD - SVRA
41%
Loosely correlated
N/A
ERAS - SVRA
41%
Loosely correlated
+1.75%
CCCC - SVRA
39%
Loosely correlated
-1.31%
More